AKT1 and acute myeloid leukemia: Consistent with previous investigations on solid tumor cancer as well as acute lymphoblastic leukemia cells [35]–[39], treatment with MK-2206 (1 μM for 6 hours) indeed resulted in effective inhibition of S473 AKT phosphorylation while leaving total AKT levels unchanged in human AML cell lines, confirming target inhibition (data not shown).